EMEA-003076-PIP01-21
Key facts
| Active substance |
Human normal immunoglobulin
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0501/2021
|
| PIP number |
EMEA-003076-PIP01-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Primary Immunodeficiency (PID)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Octapharma Pharmazeutika Produktionsges.m.b.H
Email: at1CRDGeneral@octapharma.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|